Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 9:08 PM
Ignite Modification Date: 2025-12-25 @ 6:59 PM
NCT ID: NCT01649804
Description: An AE was any untoward medical occurrence in a study participant administered a pharmaceutical product, and which did not necessarily have a causal relationship with the treatment.
Frequency Threshold: 0
Time Frame: End of Study (Week 104 or early withdrawal)
Study: NCT01649804
Study Brief: A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Tocilizumab Tocilizumab (RoActemra/Actemra) 8 mg/kg intravenously every 4 weeks for 104 weeks. Dose could be reduced due to safety reasons at any time during the study. None None 0 12 9 12 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Nasopharyngitis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (18.1) View
Otitis media SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (18.1) View
Respiratory tract infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (18.1) View
Arthropod bite SYSTEMATIC_ASSESSMENT Injury, poisoning and procedural complications MedDRA (18.1) View
White blood cell count decreased SYSTEMATIC_ASSESSMENT Investigations MedDRA (18.1) View
Intervertebral disc disorder SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (18.1) View
Intervertebral disc protrusion SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (18.1) View
Sciatica SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (18.1) View
Depression SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA (18.1) View
Dermatitis SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (18.1) View
Diarrhoea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (18.1) View
Ranula SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (18.1) View
Cystitis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (18.1) View
Influenza SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (18.1) View
Otitis externa SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (18.1) View